Neuromyelitis Optica, also referred to as Devic’s disease is a chronic condition of the brain and spinal cord, characterised by inflammation of the optic nerve (nerve neuritis), and spinal cord (myelitis). The progression of disease initiates whereby the body’s immune system mistakenly attacks healthy cells and neuronal sheath, myelin in the spinal cord and eyes.

This report provides the current prevalent population for Neuromyelitis Optica (NMO) across 27 Major Markets (USA, Canada,  France, Germany, Italy, Spain, UK, Ireland, Japan, China, South Korea, India, Belgium, Netherlands, Norway, Sweden, Finland, Austria, Switzerland, Poland, Russia, Brazil, Mexico, Argentina,  Australia) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, Neuromyelitis Optica patients grouped by diagnostic criteria, features associated with Neuromyelitis Optica, and comorbidities quantified and presented parallel to over general prevalence figures. Inclusive of the report are the sub-populations within the main disease and are included at country level across the 10-year forecast period.

Main symptoms associated with Neuromyelitis Optica include:

  • Pain in the eyes
  • Loss of vision
  • Weakness or numbness in the arms and legs
  • Paralysis of the arms and legs
  • Difficulty controlling the bladder and bowels

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global Neuromyelitis Optica market in order t target the development of future products, pricing strategies and launch plans.
  • Further insight into prevalence of the co-morbidities associated with Neuromyelitis Optica and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Identification of Neuromyelitis Optica patient sub-populations that require treatment.
  • Improved understanding of the specific markets that have the largest number of Neuromyelitis Optica patients.